Ganymed Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference

| Print |
Thursday, 19 December 2013 15:00 (UTC + 1)

Ganymed Logo

Mainz, Germany, December 19, 2013 / B3C newswire / - Ganymed Pharmaceuticals AG, a clinical-stage biopharmaceutical company developing highly selective Ideal Monoclonal Antibodies (IMABs) for the treatment of cancer, announced today that it will present at the 32nd Annual J.P. Morgan Healthcare Conference that will take place from January 13 to January 16, 2014 in San Francisco.

Ganymed’s CEO, Dr. Özlem Türeci, will provide an overview of the company’s product pipeline and clinical programs. Her presentation will take place on Tuesday January 14 from 11:30 to 12:00 Pacific Time in the Elizabethan D meeting room of the Westin St. Francis Hotel, San Francisco.

The Annual J.P. Morgan Healthcare Conference is the largest healthcare investment conference, bringing together established industry leaders and emerging fast-growth companies.

Ganymed invites you to follow Dr. Türeci's presentation via a live webcast that can be accessed through our website at www.ganymed.ag (20:30 Central European Time).


About Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Ganymed’s lead program, IMAB362, is in advanced phase II testing for gastroesophageal cancer. IMAB362 binds to the tight junction protein Claudin-18.2 which is expressed in up to 80% of gastroesophageal adenocarcinomas, 60% of pancreatic tumors as well as in other various solid tumors.

Ganymed is also developing IMAB027, a monoclonal antibody targeting GT512 which is absent in healthy adult organs, but is expressed in a wide range of solid cancers, including testicular, ovarian, uterine, and lung cancers. The company plans to initiate clinical studies with IMAB027 in the near future.

Ganymed is a private company that was founded in 2001 as a spin-off from the Universities of Mainz and Zurich. Its majority shareholder is ATS Beteiligungsverwaltung GmbH. Other investors include Future Capital AG, MIG Fonds, FCPB Gany GmbH, and private individuals.


Contact Information

Dr. Luc St-Onge
Business Development
Ganymed Pharmaceutical AG
Freiligrathstrasse 12
55131 Mainz
Germany
Tel.: +49 (0)6131 1440 100
e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Media Contact

Frank Butschbacher, CIR
Investor Relations & Communications
Tel.: +43-650-78 44 940
e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it